Peptide Test Canada
peptidetestcanada.ca
Canada's Most Trusted Independent Peptide Testing Lab

Certificate of Analysis

Lab ID: **TIR-027**

REPORTED August 14, 2026

CLIENT

VERIFY peptidetestcanada.ca/verify
EMAIL info@peptidetestcanada.ca
ORDER # PTC-WJXID7T3

SCAN TO VERIFY
PTC-L7GE4B68

END CUSTOMER

NAME NextGenPeptides.ca
EMAIL —
PHONE —
ADDRESS —

§ 01 Sample Information

FOR RESEARCH PURPOSES ONLY

Sample ID:	**TIRZ-272**	Received:	**08/11/2026**
Compound:	**Tirzepatide**	Analyzed:	**08/14/2026**
Report No.:	**COA-2026-SC-01272**	CAS:	**2023788-19-2**
Total Mass:	**60.6 mg Lyophilized**	Formula:	**$C_{225}H_{348}N_{48}O_{68}$**
Appearance:	**powder**	Mol Weight:	**4814.6 g/mol**

SAMPLE PHOTOGRAPH



§ 02 Analytical Results

Qualitative and Quantitative chemical analysis by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

	SPECIFICATION	RESULT	STATUS
Compound Test:	Tirzepatide	**Tirzepatide**	
Net Peptide Content:	10.00 mg	**9.37 mg**	
Peptide Label Accuracy:	≥ 90 %	**93.7 %**	**PASS**
Chromatographic Purity:	≥ 98 %	**99.4 %**	

Chromatographic purity is the target peptide's HPLC-MS/MS principal component analysis, expressed as a percentage of total integrated peak area (Ph. Eur. 2.2.46) — it bounds peptide-related impurities only, not excipients, counter-ions, or residual water, and is separate from net peptide content. — indicates not determined.

§ 03 LC-MS/MS Detail

METHOD B · AGILENT 1290 INFINITY II + 6495 QQQ · ESI+

PRECURSOR [M+5H]5+
963.90 Da

Quantifier transition ● MRM
963.90 › 136.10 CE 28 V



ROLE	TRANSITION	CE
● Quantifier	963.9 › 136.1	28 V
■ Qualifier	963.9 › 110.1	33 V

Agilent Poroshell 120 EC-C18 · 2.1×100 mm · 2.7 µm · Solvent A: 0.1 % formic acid in H_2O · Solvent B: 0.1 % formic acid in Acetonitrile

DISCLAIMER · RESEARCH USE ONLY
Results relate **only to the sample as received** and the tests performed — not to any other unit, lot, or batch. **For research use only**: not a certificate of quality, safety, efficacy, or regulatory compliance, and not for human or veterinary administration, clinical or diagnostic use, or label claims. SideChain Analytics does not manufacture, source, or sell the material and makes **no warranty, express or implied**; its liability shall not exceed the testing fee. This report may not be reproduced except in full.

Issued August 14, 2026